So now a company working on an anti-tau/amyloid th

Quote:

---

Alzheon announced Thursday morning it has completed a $50 million Series D round aimed to advance a Phase III study for its oral Alzheimer’s program, as well as to help prep the drug’s regulatory filings. The candidate, dubbed ALZ-801, is an oral tablet being evaluated for patients with early-stage Alzheimer’s disease....

Though Tolar hyped the data as presenting a clear path forward for the drug, outside experts threw cold water on that assessment. George Perry, the neurobiology chair at the University of Texas at San Antonio, wrote to Endpoints News in February that the data were “very over sold,” criticizing the lack of placebo controls in the study.

---